重组人脑利钠肽联合左西孟坦治疗急性失代偿性心力衰竭的临床疗效及安全性

Clinical efficacy and safety of recombinant human brain natriuretic peptide(rhBNP) combined with levosimendan in the treatment of acute decompensated heart failure(ADHF)

目的:探讨重组人脑利钠肽(rh BNP)联合左西孟坦治疗急性失代偿性心力衰竭(ADHF)的临床效果。方法:收治ADHF患者67例,随机分为研究组与参照组。参照组采用左西孟坦治疗,研究组采用rh BNP联合左西孟坦治疗,比较两组治疗效果。结果:研究组CO、MPAP、PCWP水平显著优于参照组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论:rh BNP联合左西孟坦治疗ADHF能有效减轻患者临床症状,治疗效果良好。

Objective：To explore the clinical efficacy of rh BNP combined with levosimendan in the treatment of ADHF.Methods：67 patients with ADHF were selected.They were randomly divided into the study group and the reference group.The reference group was treated with levosimendan,and the study group was treated with rh BNP combined with levosimendan.We compared the therapeutic effect of two groups.Results：In the study group,the levels of CO,MPAP and PCWP were significantly better than the reference group（P〈0.05）.There was no significant difference in the incidence of adverse reactions between groups（P〈0.05）.Conclusion：The application of rh BNP combined with levosimendan in the treatment of ADHF can effectively reduce the clinical symptoms of the patients,and the treatment effect was good.